News
TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
News
TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "TetraLogic Initiates Phase 1 Clinical Trial of TL32711 in Patients with Lymphoma"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
TetraLogic Pharmaceuticals announced that the Company has completed dosing of the first cohort in a Phase 1 clinical trial of its selective SMAC mimetic, TL32711.
The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
“The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
The Phase 1 trial is an open-label, dose-escalation study evaluating the safety and tolerability of TL32711 in adults with solid tumors or lymphoma refractory to standard therapies. The study will also assess the pharmacokinetics, pharmacodynamics and anti-tumor activity of TL32711.
“The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
“This is an important milestone for our Company and for cancer patients,” said John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals. “The ability of TL32711 to antagonize Inhibitor of Apoptosis Proteins in a selective manner represents a new broadly applicable approach to treat cancers that are normally resistant to therapies.”
Advertisement
